Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cubist Pharmaceuticals: An Overview Based on a Recent Company Presentation (CBST, No Opinion)

Introduction

I recently was invited to attend a broker sponsored conference for biotechnology companies. Altogether, there were 116 companies presenting at…
Read more…

Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)

Implications for Trius Shareholders
Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under…
Read more…

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview
We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an…
Read more…

Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius Therapeutics

The Issue
On May 31, 2012, Pfizer Inc. (PFE) and Teva (TEVA reached a settlement that licenses to Teva a generic…
Read more…

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

 

I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report…
Read more…

Trius' (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that…
Read more…